30 closest matches · ranked by relevance
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: Change From Baseline in Enhanced Liver Fibrosis Score at Week 48 — -0.071; 0.125; -0.213; 0.263 score on a scale
Cirrhosis, Liver
Primary: Enrollment Rate — 20; 20 Participants
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Liver Fibrosis · Cirrhosis · Chronic Hepatitis B
Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12) — 100.0…
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)…
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
Hepatocellular Carcinoma · Cirrhosis
Primary: HCC Screening Completion — 27.6; 54.5; 54.1 Percentage of participants
Hepatitis C, Chronic · Liver Cirrhosis
Primary: Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response) — 41; 40; 21 Participants
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
Cirrhosis · Aerobic Exercises · Lifestyle Modification
Primary: Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN — 75.87; 55.13; -4.77; -14.91 milliseconds — p=0.64
Hepatitis C Virus Infection · Chronic Hepatitis C · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.3 percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.2; 92.2 Percentage of participants — p=<0.001
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Hepatitis C · Cirrhosis · Portal Hypertension
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 72.0; 0; 71.4 percentage of participants
Liver Cirrhosis
Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 78.1; 72.2; 80.0; 85.7 percentage of participants
Chronic Hepatitis C Infection · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment — 91.8; 96.5 Percentage of participants
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants…
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
NASH - Nonalcoholic Steatohepatitis · Cirrhosis · Portal Hypertension
Primary: Number of Subjects With Matched Clinically Significant Portal Hypertension Based on Hepatic Venous Pressure Gradient (HVPG) and Methacetin Breath Test (MBT) — 190…
Chronic Hepatitis C · Decompensated Cirrhosis · Hepatitis C Virus
Primary: Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2 — 100; 95.8 percentage of participants
Hepatitis B, Chronic
Primary: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 — 6.045 Events per person-year